Items Tagged ‘Empliciti’

July 13th, 2017

Four-Year Follow-up with Empliciti Plus Revlimid in Patients with Advanced Multiple Myeloma Shows Long-term Beneift

By

Four-year follow-up data from the Phase 3 ELOQUENT-2 clinical trial in which Empliciti (elotuzumab) plus Revlimid (lenalidomide) continued to demonstrate effectiveness in patients with relapsed/refractory multiple myeloma compared to patients treated with Revlimid alone were recently presented in an oral session today during the 22nd Congress of the European Hematology Association in Madrid, Spain.  Combination […]

View full entry

Tags: cancer precision medicine, ELOQUENT-2 clinical trial, elotuzumab, Empliciti, lenalidomide, Multiple Myeloma, News, revlimid


December 7th, 2015

FDA Approves Empliciti for Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for the treatment of patients with multiple myeloma who have received prior therapies. The indication specifies that Empliciti is to be used in combination with lenalidomide and dexamethasone for the treatment of patients who have received one to three prior therapies for multiple […]

View full entry

Tags: dexamethasone, elotuzumab, Empliciti, fda, lenalidomide, Multiple Myeloma, News, Recurrent Multiple Myeloma, SLAMF7